Clinical trials: sponsored by ANRS, Emerging Infectious Diseases
Hepatitis C, Testing
Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia
Objectives Principal objective: to compare the effectiveness of a community-based intervention to a facility-based intervention to improve the combined-testing uptake (Antibody + RNA) of HCV infection among general population…
- Trial name
- Cam-C (NCT03992313)
- Testing
- Community-based HCV rapid test, Facility-based HCV rapid test, Plasmatic HCV viral load
- Where
- 2 sites in Cambodia
- Volunteers
- 7,692 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
SARS-CoV Infection, Covid19
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
This is a prospective, multicentric, non comparative study aiming to evaluate the clinical and virological evolution of high-risk patients infected with SARS-CoV-2 treated withtin the framework of a cohort ATU ('Autorisation…
- Trial name
- NCT04885452
- Testing
- biobank
- Where
- 37 sites in France
- Volunteers
- 756 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
- Trial name
- NCT06255626
- Testing
- CD40.RBDv vaccin (SARS-Cov2 Vaccin)
- Where
- 2 sites in France
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)
In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral…
- Trial name
- MULTIVIR2025 (NCT06842706)
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection
A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide
The main objective of the study is to evaluate the diffusion of bictegravir and associated backbone (tenofovir alafenamide and emtricitabine) in HIV-1 chronic patients in the main putative reservoirs, namely inguinal lymph nodes…
- Trial name
- NCT05222945
- Testing
- Biopsies and bloood samplings
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, HBV Coinfection
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple…
- Trial name
- BI-LIGHT (NCT06338826)
- Testing
- TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
- Volunteers
- 140 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis D, Chronic, Hepatitis B, Chronic
National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses
This is a multicentre observational study with prospective and retrospective data collection and retrospective data collection and biological collection from patients with HBV/HDV co-infection.
- Trial name
- HEPDELTA (NCT04166266)
- Testing
- Blood draw for the laboratory assessment
- Where
- 38 sites in France
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis
DRug Use & Infections in ViEtnam: TuBerculosis Control
The overarching purpose of the proposed research is to demonstrate that a targeted, multi-component community-based intervention among PWID in Hai Phong will decrease TB prevalence among this very high-risk population.
- Trial name
- DRIVE-TB (NCT05655702)
- Testing
- Community based TB intervention
- Where
- 2 sites in Vietnam
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms
The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS…
- Trial name
- PediacamNEG (NCT06302933)
- Testing
- Blood sampling
- Where
- 3 sites in Cameroon
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Aging With HIV and Neurocognitive Decline, a Follow-up Study
The ANRS ( Agence Nationale de Recherches sur le Sida et les Hépatites virales) 0093s Aging HAND study is to assess whether PLHIV (People Living with HIV) initially between 55-70 years of age at baseline analysis under…
- Trial name
- AgingHAND (NCT05385588)
- Testing
- cognitive functional assessment
- Where
- 11 sites in France
- Volunteers
- 282 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, Immunocompromised Host
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concerns
- Trial name
- PRECOVIM (NCT05216588)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV
Outcome at 5 Years of Early Treated HIV Infected Infants in the PEDIACAM Project
This study aims to assess the long-term outcomes of children infected with HIV, having participated in the ANRS 12140 PediacamI study, in terms of: clinical and immunovirological response to ARV therapy, long-term ARV tolerance…
- Trial name
- PEDIACAM (NCT02043418)
- Where
- 3 sites in Cameroon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, COVID-19 Drug Treatment
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
In January 2020, the new SARS-CoV-2 coronavirus was identified in China. The disease caused by this coronavirus was named COVID-19 by the World Health Organization (WHO).
- Conditions
- COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- INTENSE-COV (NCT04466241)
- Testing
- Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet
- Where
- 2 sites in Côte d’Ivoire
- Volunteers
- 294 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV/AIDS and Infections
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART…
- Trial name
- RHIVIERA-02 (NCT05300035)
- Testing
- Recombinant human monoclonal antibody (bNAbs)
- Where
- 17 sites in France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy Adults
Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers
FIRST PART: DOSE ESCALATION Multicenter double-blind placebo controlled phase I dose-escalation trial that will be conducted in France and Switzerland to evaluate different dose levels of CD40.HIVRI.Env (adjuvanted with Hiltonol)…
- Trial name
- NCT04842682
- Testing
- Solo 0.3 group, Solo 1 group, Solo 3 group
- Where
- 3 sites in France, Switzerland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV
Prevalence of Histoplasmosis in HIV + Patients with a Rapid Diagnostic Test in West Indies
Histoplasma capsulatum var. capsulatum histoplasmosis is the leading cause of acquired immunodeficiency syndrome (AIDS) and death in French Guiana and probably in the Amazon.
- Trial name
- EDIRAPHIS (NCT01884779)
- Where
- 7 sites in France, Suriname
- Volunteers
- 727 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, Yellow Fever
Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination
ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination
- Trial name
- NCT05450770
- Testing
- Yellow fever vaccination (STAMARIL)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Assisted Notification of Partners of Men Having Sex With Men Discovering Their Seropositivity
The context of HIV has changed dramatically this last two decades with the availability of highly active and well tolerated antiretroviral therapies, and the extension of prevention methods to include treatment as prevention of…
- Trial name
- NotiVIH (NCT06419491)
- Testing
- Partner notification by a trained counsellor
- Volunteers
- 400 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, Vaccine Reaction
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete…
- Conditions
- COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
- Trial name
- CoviComMali (NCT05409261)
- Testing
- Ad26.COV2.S
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, Vaccine Adverse Reaction
Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea
Phase II, non-randomized, open-label, comparative, single center national trial in Guinea, aimed to assess the humoral vaccine immune response induced by BBIBP-CorV vaccine in 200 adults aged between 18 and 45 years or 55 or…
- Conditions
- COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection, Healthy Volunteer
- Trial name
- CovicompareG (NCT05409300)
- Testing
- BBIBP-CorV
- Where
- 2 sites in Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases